免疫检查点抑制剂纳武利尤单抗致免疫相关性胰腺炎不良反应一例  

Immune-Related Pancreatitis Caused by Immune Checkpoint Inhibitor Nivolumab:Report of One Case

作　　者：许峰[1] 沈珠[1] 陶宏[1] 朱珠[1] 陶家龙[2] 冯正阳 XU Feng;SHEN Zhu;TAO Hong;ZHU Zhu;TAO Jialong;FENG Zhengyang(Department of Pharmacy,the Second Affiliated Hospital of Soochow University,Suzhou,Jiangsu 215004,China;Department of Oncology,the Second Affiliated Hospital of Soochow University,Suzhou,Jiangsu 215004,China)

机构地区：[1]苏州大学附属第二医院药剂科,江苏苏州215004 [2]苏州大学附属第二医院肿瘤科,江苏苏州215004

出　　处：《中国医学科学院学报》2023年第2期351-354,共4页Acta Academiae Medicinae Sinicae

基　　金：江苏省药学会奥赛康医院药学基金(A202117);吴阶平医学基金(320.6750.2020-12-72);江苏省医学会天晴医院药学基金(Q2019060)。

摘　　要：免疫检查点抑制剂(ICI)在肿瘤免疫领域取得了突破性进展,同时也诱发了诸多免疫相关的不良反应。虽然ICI总体各级不良反应发生率较高,但也有一些不良反应临床罕见,如免疫相关性胰腺炎。本文对1例晚期胃癌经纳武利尤单抗治疗后并发免疫相关性胰腺炎的病例进行不良反应原因鉴别、处置分析,并探讨免疫相关性胰腺炎的发生率及危险因素,以提高医师对ICI罕见不良反应的临床诊疗和用药安全。In recent years,great progress has been achieved in the application of immune checkpoint inhibitors(ICI)in tumor immunotherapy.However,a variety of adverse reactions induced by ICI have been reported.Despite the high overall incidence of adverse reactions caused by ICI,some adverse reactions,such as immune-related pancreatitis,are rare in clinical practice.In this paper,a case of immune-related pancreatitis after treatment of advanced gastric cancer with nivolumab was identified.We analyzed the cause,treatment,incidence,and risk factors of the adverse reaction,aiming to improve the clinical diagnosis,treatment,and safe medication of rare adverse reactions associated with ICI.

关 键 词：免疫检查点抑制剂 免疫相关不良反应 免疫相关性胰腺炎 

分 类 号：R751[医药卫生—皮肤病学与性病学]